Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252382
Status:
COMPLETED
Last Update Posted:
2018-09-24
First Post:
2005-11-09
Brief Title:
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Sponsor:
Sunesis Pharmaceuticals
Organization:
Sunesis Pharmaceuticals
Study Overview
Official Title:
Phase 2 Open-Label Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the objective tumor response rate based on the RECIST criteria to SNS-595 as a second-line therapy in patients with advanced NSCLC
Detailed Description:
Other objectives of this study are to assess the safety tumor response time to disease progression survival rate and to explore several potential biomarkers to see how these levels change after administration of SNS-595
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None